How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Idiopathic Pulmonary Fibrosis (IPF) Drugs Market
- By Drug Class: Antifibrotic Agents, Immunosuppressants, Anti-inflammatory Agents, Combination Therapies
- By Route of Administration: Oral, Inhalation, Intravenous
- By Mechanism of Action: Tyrosine Kinase Inhibitors, Pirfenidone-based Agents, Nintedanib-based Agents, Corticosteroids
- By Patient Population: Idiopathic Pulmonary Fibrosis (IPF) Patients, Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patients, Patients with Mild to Moderate IPF, Patients with Severe IPF
- By Treatment Line: First-line Therapy, Second-line Therapy, Combination Therapy
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Antifibrotic Agents leads By Drug Class at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 12 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 282 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.174 →
- 12 Company Profiles 12 players: SWOT & benchmarking p.182 →
Full report · locked preview
Everything inside the Idiopathic Pulmonary Fibrosis (IPF) Drugs Market report
A complete, evidence-based study - 12 chapters and 118 sections covering market size, segmentation across 5 axes, regional analysis and 12 company profiles, forecast to 2033.
Segmentation covered
Drug Class 4
Route of Administration 3
Mechanism of Action 4
Patient Population 4
Treatment Line 3
Companies profiled
Boehringer Ingelheim
Roche (Genentech)
Galapagos NV
Mitsubishi Tanabe Pharma Corporation
Bristol-Myers Squibb
Veracyte Inc.
FibroGen Inc.
Shionogi & Co. Ltd.
AbbVie Inc.
Johnson & Johnson
Gilead Sciences Inc.
AstraZeneca
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
12 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Boehringer Ingelheim
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Roche (Genentech)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Galapagos NV
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Mitsubishi Tanabe Pharma Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Bristol-Myers Squibb
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Veracyte Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →FibroGen Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Shionogi & Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →AbbVie Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Johnson & Johnson
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Gilead Sciences Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.214 →AstraZeneca
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$1,663M by 2033 · 5.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Antifibrotic Agents56.0
- Immunosuppressants14.1
- Anti-inflammatory Agents11.5
- Combination Therapies18.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$360.6M → $560.6M · 5.7%
Europe$251.3M → $417.0M · 6.5%
Asia Pacific$229.5M → $389.5M · 6.8%
Latin America$142.0M → $215.5M · 5.4%
Middle East and Africa$109.3M → $167.1M · 5.5%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.342026
5.342027
5.372028
5.382029
5.392030
5.402031
5.422032
5.422033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Boehringer Ingelheim13.8
- Roche (Genentech)9.6
- Galapagos NV12.8
- Mitsubishi Tanabe Pharma Corporation13.7
- Bristol-Myers Squibb11.6
- Veracyte Inc.10.5
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Drug Class22.4%
Route of Administration29.2%
Mechanism of Action14.3%
Patient Population8.6%
Treatment Line25.4%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.0
- Europe23.8
- Asia Pacific22.3
- Latin America12.3
- Middle East and Africa9.5
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | 88 | 76 | 76 | 91 | 95 | 80 | 84 |
| Roche (Genentech) | 77 | 87 | 73 | 74 | 82 | 79 | 79 |
| Galapagos NV | 63 | 65 | 79 | 75 | 66 | 81 | 72 |
| Mitsubishi Tanabe Pharma Corporation | 58 | 77 | 60 | 61 | 69 | 59 | 64 |
| Bristol-Myers Squibb | 65 | 61 | 68 | 70 | 71 | 58 | 66 |
| Veracyte Inc. | 70 | 51 | 62 | 71 | 71 | 58 | 64 |
| FibroGen Inc. | 54 | 60 | 46 | 57 | 63 | 63 | 57 |
| Shionogi & Co. Ltd. | 39 | 38 | 52 | 56 | 49 | 41 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Boehringer Ingelheim
- Roche (Genentech)
- Galapagos NV
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim | ◐ | ◐ | ◐ | ◐ | ✓ | ✓ |
| Roche (Genentech) | ◐ | ✓ | ◐ | ◐ | ◐ | ◐ |
| Galapagos NV | − | ◐ | ◐ | ✓ | ✓ | ◐ |
| Mitsubishi Tanabe Pharma Corporation | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Bristol-Myers Squibb | ◐ | ✓ | ✓ | ◐ | − | ◐ |
| Veracyte Inc. | − | − | ◐ | − | ◐ | − |
| FibroGen Inc. | ◐ | − | − | − | − | ◐ |
| Shionogi & Co. Ltd. | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Boehringer Ingelheim84
2Roche (Genentech)79
3Galapagos NV72
4Bristol-Myers Squibb66
5Mitsubishi Tanabe Pharma Corporation64
6Veracyte Inc.64
7FibroGen Inc.57
8Shionogi & Co. Ltd.46
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Boehringer IngelheimRoche (Genentech)
Challenger1
Strong scale, closing on the leaders.
Galapagos NV
Contender4
Focused players with pockets of strength.
Mitsubishi Tanabe Pharma CorporationBristol-Myers SquibbVeracyte Inc.FibroGen Inc.
Niche1
Specialists in a single segment or region.
Shionogi & Co. Ltd.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Drug Class in North America, then scale across Idiopathic Pulmonary Fibrosis (IPF) Drugs Market — a $479M beachhead inside a $7.65B market.
Beachhead (SOM)$479Mobtainable near-term
Serviceable (SAM)$2.68Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion86 fit
Antifibrotic Agents
Best fit — highest urgency & budget in Drug Class.
Economic buyer77 fit
Immunosuppressants
Strong fit — clear ROI and a fast path to value.
End user66 fit
Anti-inflammatory Agents
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Drug Class in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Route of Administration & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Mechanism of Action
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel26%
Digital / self-serve22%
Marketplaces10%
Positioning & messaging
§GTM 2 · p.194 →For Drug Class leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Idiopathic Pulmonary Fibrosis (IPF) Drugs Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified38%
Sales qualified25%
Evaluation15%
Closed-won6%
$14.8KCAC
$70KLTV
4.8:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Idiopathic Pulmonary Fibrosis (IPF) Drugs Market is a high-growth opportunity — $6.41B by 2033, compounding at 11.3%.
TAM · 2025$2.72Btoday
TAM · 2033$6.41Bforecast
CAGR11.3%2027–2033
Cumulative$39.0Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$6.41BTotal addressable market
SAM$2.55BServiceable available market
SOM$539MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →11.3% CAGR
Demand compounds through 2033, outpacing GDP across Drug Class.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Drug Class moving from early to mainstream — durable secular demand.
Consolidation upside
12+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$6.41BLarge & growingTAM by 2033 at 11.3% CAGR
$2.55BServiceable nowreachable with today’s model
$539MBeachhead winobtainable near-term share
12+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$5.00BBear7.4% CAGR
$6.41BBase11.3% CAGR
$8.20BBull15.0% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Route of Administration optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Idiopathic Pulmonary Fibrosis (IPF) Drugs Market — a $2.71B market by 2033. Plan: grow share from 11.6% to 18.9%.
Market size · 2033$2.71Btotal addressable
Market CAGR3.7%2027–2033
Target share18.9%from 11.6% today
Revenue ambition$513Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 11.6% | 18.9% | At risk |
| Revenue | $314M | $513M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 33.2% | 42.5% | At risk |
| Customer retention | 88.9% | 94.2% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Drug Class
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Route of Administration capability
A defensible second engine — invest in Route of Administration to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Drug Class share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Route of Administration
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $70M capacity & capability investment
- Greenlight bolt-on M&A in Route of Administration
- Authorise North America expansion plan
- Fund R&D program for Drug Class leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeAhead
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Idiopathic Pulmonary Fibrosis (IPF) Drugs Market conversation — a $3.82B market you can size, segment and defend in minutes.
Market size · 2033$3.82Btotal opportunity
Growth6.6%CAGR to 2033
Addressable buyers1,520+accounts in scope
Typical ROI6.7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Drug Class
Goal Grow share in Drug Class
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.7×return on cost, year one
< 3 mopayback period
$47K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
12+players profiled in this market
Coverage includes
Boehringer IngelheimRoche (Genentech)Galapagos NVMitsubishi Tanabe Pharma CorporationBristol-Myers SquibbVeracyte Inc.FibroGen Inc.Shionogi & Co. Ltd.+4 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Idiopathic Pulmonary Fibrosis (IPF) Drugs Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Idiopathic Pulmonary Fibrosis (IPF) Drugs Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Idiopathic Pulmonary Fibrosis Disease Treatment Market
Market size, share, segmentation and regional forecast.
$476M market · 2025 base year
View reportIdiopathic Membranous Nephropathy Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportIdiopathic Hypersomnia Treatment Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportIdiopathic Gastroparesis Drugs Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportIDH1 Antibody Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportIndustrial Automation In Life Sciences Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportIdelalisib(CAL-101) Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportIdarubicin Market
Market size, share, segmentation and regional forecast.
$874M market · 2025 base year
View reportIdarubicin Hydrochloride Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportIdarubicin HCl Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportModular Cleanroom Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportICU Wall-mounted Bed Head Unit Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.